Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENSURE-GSD1b: Empagliflozin for Neutropenia in Glycogen Storage Disease Type Ib
jRCTs031250458Recruiting
- Sponsor
- National Center for Child Health and Development
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of empagliflozin in glycogen storage disease type 1b and neutropenia, sponsored by National Center for Child Health and Development. Primary endpoint: Change in absolute neutrophil count (ANC) from baseline to final day of treatment. Started Oct 2025; status: recruiting.
02
Drugs
empagliflozin
03
Conditions
glycogen storage disease type 1bneutropenia
Beyond the preview
Go deeper on jRCTs031250458.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031250458.